Browse FN1

Summary
SymbolFN1
Namefibronectin 1
Aliases CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix.
Domain PF00039 Fibronectin type I domain
PF00040 Fibronectin type II domain
PF00041 Fibronectin type III domain
Function

Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization. Participates in the regulation of type I collagen deposition by osteoblasts.; FUNCTION: Anastellin binds fibronectin and induces fibril formation. This fibronectin polymer, named superfibronectin, exhibits enhanced adhesive properties. Both anastellin and superfibronectin inhibit tumor growth, angiogenesis and metastasis. Anastellin activates p38 MAPK and inhibits lysophospholipid signaling.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001558 regulation of cell growth
GO:0001704 formation of primary germ layer
GO:0001706 endoderm formation
GO:0001818 negative regulation of cytokine production
GO:0002526 acute inflammatory response
GO:0002576 platelet degranulation
GO:0006887 exocytosis
GO:0006929 substrate-dependent cell migration
GO:0006931 substrate-dependent cell migration, cell attachment to substrate
GO:0006953 acute-phase response
GO:0007044 cell-substrate junction assembly
GO:0007160 cell-matrix adhesion
GO:0007161 calcium-independent cell-matrix adhesion
GO:0007369 gastrulation
GO:0007409 axonogenesis
GO:0007492 endoderm development
GO:0008360 regulation of cell shape
GO:0008361 regulation of cell size
GO:0009306 protein secretion
GO:0010720 positive regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010770 positive regulation of cell morphogenesis involved in differentiation
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0010952 positive regulation of peptidase activity
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0016049 cell growth
GO:0018149 peptide cross-linking
GO:0022604 regulation of cell morphogenesis
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0030307 positive regulation of cell growth
GO:0030335 positive regulation of cell migration
GO:0030516 regulation of axon extension
GO:0031346 positive regulation of cell projection organization
GO:0031589 cell-substrate adhesion
GO:0032535 regulation of cellular component size
GO:0033622 integrin activation
GO:0034329 cell junction assembly
GO:0034330 cell junction organization
GO:0034446 substrate adhesion-dependent cell spreading
GO:0035987 endodermal cell differentiation
GO:0038044 transforming growth factor-beta secretion
GO:0040017 positive regulation of locomotion
GO:0043062 extracellular structure organization
GO:0045055 regulated exocytosis
GO:0045666 positive regulation of neuron differentiation
GO:0045773 positive regulation of axon extension
GO:0045785 positive regulation of cell adhesion
GO:0045862 positive regulation of proteolysis
GO:0045927 positive regulation of growth
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048146 positive regulation of fibroblast proliferation
GO:0048514 blood vessel morphogenesis
GO:0048588 developmental cell growth
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048675 axon extension
GO:0050663 cytokine secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050709 negative regulation of protein secretion
GO:0050710 negative regulation of cytokine secretion
GO:0050769 positive regulation of neurogenesis
GO:0050770 regulation of axonogenesis
GO:0050772 positive regulation of axonogenesis
GO:0050900 leukocyte migration
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051224 negative regulation of protein transport
GO:0051272 positive regulation of cellular component movement
GO:0051962 positive regulation of nervous system development
GO:0052547 regulation of peptidase activity
GO:0060560 developmental growth involved in morphogenesis
GO:0061387 regulation of extent of cell growth
GO:0061564 axon development
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0090066 regulation of anatomical structure size
GO:1903531 negative regulation of secretion by cell
GO:1904235 regulation of substrate-dependent cell migration, cell attachment to substrate
GO:1904237 positive regulation of substrate-dependent cell migration, cell attachment to substrate
GO:1904950 negative regulation of establishment of protein localization
GO:1990138 neuron projection extension
GO:2000147 positive regulation of cell motility
GO:2001201 regulation of transforming growth factor-beta secretion
GO:2001202 negative regulation of transforming growth factor-beta secretion
Molecular Function GO:0002020 protease binding
GO:0005178 integrin binding
GO:0005518 collagen binding
GO:0005539 glycosaminoglycan binding
GO:0008047 enzyme activator activity
GO:0008201 heparin binding
GO:0016504 peptidase activator activity
GO:0050839 cell adhesion molecule binding
GO:0061134 peptidase regulator activity
GO:1901681 sulfur compound binding
Cellular Component GO:0005577 fibrinogen complex
GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0005605 basal lamina
GO:0005793 endoplasmic reticulum-Golgi intermediate compartment
GO:0016324 apical plasma membrane
GO:0030141 secretory granule
GO:0031091 platelet alpha granule
GO:0031093 platelet alpha granule lumen
GO:0031983 vesicle lumen
GO:0034774 secretory granule lumen
GO:0044420 extracellular matrix component
GO:0045177 apical part of cell
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0072562 blood microparticle
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04512 ECM-receptor interaction
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-422475: Axon guidance
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1474244: Extracellular matrix organization
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-1566977: Fibronectin matrix formation
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-354194: GRB2
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-354192: Integrin alphaIIb beta3 signaling
R-HSA-216083: Integrin cell surface interactions
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-5674135: MAP2K and MAPK activation
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-6802957: Oncogenic MAPK signaling
R-HSA-6802955: Paradoxical activation of RAF signaling by kinase inactive BRAF
R-HSA-76009: Platelet Aggregation (Plug Formation)
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-6802952: Signaling by BRAF and RAF fusions
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-6802949: Signaling by RAS mutants
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-6802948: Signaling by high-kinase activity BRAF mutants
R-HSA-6802946: Signaling by moderate kinase activity BRAF mutants
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
R-HSA-372708: p130Cas linkage to MAPK signaling for integrins
Summary
SymbolFN1
Namefibronectin 1
Aliases CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FN1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FN1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29655625colon carcinomaPromote immunityThis technology was used for vaccination against a marker of the tumor vasculature, the well-known extra domain B (EDB) of fibronectin.
Summary
SymbolFN1
Namefibronectin 1
Aliases CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FN1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFN1
Namefibronectin 1
Aliases CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5490.387
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.690.852
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4460.87
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9390.163
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0210.784
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8230.871
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4840.589
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5840.843
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4170.897
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3370.909
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5750.895
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2190.379
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.12.78.40.12
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.13.47.70.176
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.511.8-2.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)1311018.2-18.20.199
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59400400.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.17.71.41
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolFN1
Namefibronectin 1
Aliases CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FN1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFN1
Namefibronectin 1
Aliases CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FN1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FN1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFN1
Namefibronectin 1
Aliases CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FN1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFN1
Namefibronectin 1
Aliases CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FN1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFN1
Namefibronectin 1
Aliases CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FN1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFN1
Namefibronectin 1
Aliases CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location2q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FN1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FN1.
ID Name Drug Type Targets #Targets
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119
DB06245LanoteplaseBiotechANXA2, CALR, CANX, CLEC3B, F10, FGA, FN1, KLK1, KRT8, LAMA1, LAMA3 ......17
DB08888OcriplasminBiotechA2M, FN1, SERPINF23